EUVIMEDSkopri EUVIMED
Crossref

Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil

Israa Ahmad Cheikh, Berthe Hayar, Noorhan Ghanem, Lara Al Saleh, Chirine El-Baba, Sadaf Al-Hadeethi, Riyad El-Khoury, Julnar Usta, Nadine Darwiche iD

Molecular Carcinogenesis · 2025-07 · 64 (7) · 1222-1235

DOI: 10.1002/mc.23920 ↗

At a glance

Journal article in Molecular Carcinogenesis, published online on 2025-04-16. Written by Israa Ahmad Cheikh and 8 co-authors. Institution: Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon. Major MEDLINE topics: Fluorouracil, Pentose Phosphate Pathway, Colorectal Neoplasms, 6-Aminonicotinamide. Cited 5 times so far (Crossref); 29 references. Funded by: This research was supported by the Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon to N.D.11.543819.511….

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Colorectal cancer (CRC) is a significant global health concern with rising incidence and mortality rates. 5‐Fluorouracil (5‐FU) is the standard chemotherapy for CRC but is often constrained by resistance and toxicity, highlighting the need for more efficient treatments. The pentose phosphate pathway (PPP), a glucose metabolic shunt, is significantly upregulated in CRC to support nucleotide synthesis and redox balance. Therefore, we hypothesized that targeting the PPP decreases CRC cell growth, reduces tumor progression, and improves 5‐FU therapy. Consequently, we investigated the anti‐tumor activities, cell death mechanism, and mode of action of the PPP inhibitor, 6‐aminonicotinamide (6‐AN), and 5‐FU alone or in combination against CRC. We used human CRC cell lines with different p53 and 5‐FU resistance statuses and a CRC xenograft model. Our findings show that 6‐AN reduced the viability of human CRC cells independently of their p53 and 5‐FU resistance profile, with its effect further enhanced in combination with 5‐FU. The 6‐AN/5‐FU combination treatment synergized by reducing the total dehydrogenase activity of the PPP, inducing oxidative stress, and promoting senescence in CRC cells. Furthermore, 6‐AN treatment significantly decreased tumor growth in a CRC xenograft mouse model. However, combining 6‐AN with 5‐FU did not reduce tumor volume significantly, highlighting the complexities of translating in vitro findings to animal models. These results suggest that interfering with the PPP activity suppresses CRC cell growth and may reduce 5‐FU resistance. This study underscores targeting cancer metabolism as a novel therapeutic strategy to minimize drug resistance and to improve CRC therapeutic outcomes.

Subjects

MeSH terms (MEDLINE)

FluorouracilPentose Phosphate PathwayColorectal Neoplasms6-AminonicotinamideAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationDrug Resistance, NeoplasmMice, NudeTumor Suppressor Protein p53Apoptosis

Author keywords

5‐fluorouracil6‐aminonicotinamidecancer therapycolorectal cancerpentose phosphate pathway

Substances

Fluorouracil6-AminonicotinamideTumor Suppressor Protein p53

Authors and institutions

  • Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
  • Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon.

ORCID profiles: Nadine Darwiche

Funding

  • This research was supported by the Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon to N.D.11.543819.511…

Cite

APA

Cheikh, I. A., Hayar, B., Ghanem, N., Saleh, L. A., El-Baba, C., Al-Hadeethi, S., El-Khoury, R., Usta, J., & Darwiche, N. (2025). Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil. Molecular Carcinogenesis, 64(7), 1222-1235. https://doi.org/10.1002/mc.23920

Vancouver

Cheikh IA, Hayar B, Ghanem N, Saleh LA, El-Baba C, Al-Hadeethi S, et al. Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil. Molecular Carcinogenesis. 2025;64(7):1222-1235. doi:10.1002/mc.23920

BibTeX
@article{Cheikh2025,
  author = {Cheikh, Israa Ahmad and Hayar, Berthe and Ghanem, Noorhan and Saleh, Lara Al and El-Baba, Chirine and Al-Hadeethi, Sadaf and El-Khoury, Riyad and Usta, Julnar and Darwiche, Nadine},
  title = {Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  volume = {64},
  number = {7},
  pages = {1222--1235},
  doi = {10.1002/mc.23920}
}
Start for free →